small nuclear ribonucleoprotein polypeptide C pseudogene 20Genealiases: []
Q-omics provides the consensus-scored SNRPCP20 profile across patient tissues and cancer cell-line models. SNRPCP20 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNRPCP20 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, SNRPCP20 RNA expression shows 6,099 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where SNRPCP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP20 survival associations across molecular data types. SNRPCP20 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP20 RNA expression–survival associations across cancer types. High SNRPCP20 expression shows unfavorable associations in COAD, CHOL, OV, MESO, PCPG and LIHC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNRPCP20 RNA expression.
This table summarizes SNRPCP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP20 shows lower tumor expression in THCA. The THCA box plot shows higher SNRPCP20 RNA expression in normal versus tumor tissue (log2 FC = −0.101, t-test p = .015).
This table shows molecular features associated with SNRPCP20 in patient tissues and cancer cell lines. In patient samples, SNRPCP20 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
